Repeat Dose Study in Male Healthy Volunteer Smokers

NCT ID: NCT00615576

Last Updated: 2017-08-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-03-26
• Study Completion Date: 2008-07-24

Brief Summary

This is a 4 to 6 week study to look at the safety and PK profile of SB656933 in healthy male smokers

Conditions

Pulmonary Disease, Chronic Obstructive

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT

Study Groups

Subjects receiving SB-656933

Eligible subjects will be randomized to receive once daily doses of 100 milligrams of SB- 656933 for 14 days.

Group Type: EXPERIMENTAL

SB-656933

Intervention Type: DRUG

SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.

Subjects receiving placebo

Eligible subjects will be randomized to receive placebo for 14 days.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.

Interventions

SB-656933

SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.

Intervention Type: DRUG

Placebo

A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy adult male smokers who are between 18-65 years of age with normal genitourinary anatomy based on physical examination.
• The subjects should have a normal colour Doppler epididymal ultrasound (normal blood flow and epididymal morphology) at screening.
• The first 10 mL of urine voided (VB1) should be normal at screening and pre-dose.
• Male subjects must agree to abstain from or use a condom during sexual intercourse with pregnant females; or use a condom/spermicide, in addition to having their female partner use another form of contraception, such as an IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation, if engaging in sexual intercourse with a female partner who could become pregnant. This criterion must be followed from the time of the first dose of study medication until 84 days after the last dose of study medication.
• The subject has a QTc(B) <450msec at screening or prior to dosing
• Body weight = 50 kg (110 pounds) and body mass index (BMI) between 19 and 30 inclusive where: BMI =weight in kg/(height in meters)2
• Healthy male smokers must smoke more than 10 cigarettes per day, for at least 2 months prior to screening and less than 30 cigarettes per day at the time of enrolment.
• Subjects with Forced Expiratory Volume (FEV1)=80% predicted and FEV1/Forced Vital Capacity (FVC) ratio=0.7.
• Signed and dated written informed consent prior to admission to the study
• The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion Criteria

• Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination, or 12-lead ECG.
• The subject has liver function tests (LFT) elevated above the reference range at pre-study screening that remain elevated with a repeat LFT (to be discussed with the sponsor, if necessary).
• Subjects with absolute neutrophil count (ANC) = 2.0x109/L.
• Subjects who have previously been exposed to testicular radiotherapy.
• Subjects who have had previous testicular or prostate surgery including vasectomy.
• History of prostatitis, epididymitis, epididymal cysts, structural abnormalities or testicular cancer.
• Subjects with abnormalities of the renal tract, renal stones or history of Urinary Tract Infections (UTI's).
• Positive drug or alcohol test at screening or prior to dosing.
• Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody at screening
• Use of prescription or non-prescription medication in the last 7 days or 5 half-lives (whichever is longer) , particularly drugs that are P450 CYP3A4, CYP2B6, CYP2C8 or OATP1B1 substrates with a narrow therapeutic index , and including vitamins and herbal remedies such as St John's Wort prior to dose of study medication.
• Consumption of grapefruit or grapefruit juice within seven days prior to the first dose of study medication.
• Donation of blood in excess of 500 mL within a 56 day period prior to dosing.
• Exposure to more than 3 new chemical entities within 12 months prior to the first dosing day.
• Participation in a trial with any drug within 3 months before the start of the study or participation in a trial with a new chemical entity within 4 months before the start of the study.
• Are receiving treatment for smoking cessation.
• Are using tobacco products other than cigarettes (e.g. pipes, cigars, snuff, chewing tobacco).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

London, , United Kingdom

Countries

United Kingdom

Other Identifiers

CR2111256

Identifier Type: -

Identifier Source: org_study_id